H-BIG 1.5 UNIT
HEPATITIS B IMMUNOGLOBULIN (HUMAN) : 1.5 UNIT · DIN 00780251 · ABBOTT LABORATORIES, LIMITED
Health Canada status: CANCELLED POST MARKET
What is H-BIG?
H-BIG 1.5 UNIT contains HEPATITIS B IMMUNOGLOBULIN (HUMAN) : 1.5 UNIT. It is listed in the Health Canada Drug Product Database under DIN 00780251, held by ABBOTT LABORATORIES, LIMITED, supplied as LIQUID for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 18-Aug-1997. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00780251 |
|---|---|
| Brand name | H-BIG |
| Generic / active ingredient | HEPATITIS B IMMUNOGLOBULIN (HUMAN) : 1.5 UNIT |
| Manufacturer | ABBOTT LABORATORIES, LIMITED |
| Strength | 1.5 UNIT |
| Dosage form | LIQUID |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J06BB04 HEPATITIS B IMMUNOGLOBULIN |
| AHFS class | 80:04.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 18-Aug-1997 |
| Original market date | 1988-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J06BB04 HEPATITIS B IMMUNOGLOBULIN. 3 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEPAGAM B | 312 UNIT | SOLUTION | KI BIOPHARMA LLC | MARKETED | DIN 02290979 |
| HYPERHEP B | 110 UNIT / 0.5 ML | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02520125 |
| HYPERHEP B | 220 UNIT | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02520001 |
| HYPERHEP B | 220 UNIT | SOLUTION | GRIFOLS THERAPEUTICS LLC | APPROVED | DIN 02520133 |
| HYPERHEP B S/D | 220 UNIT | SOLUTION | GRIFOLS THERAPEUTICS LLC | CANCELLED PRE MARKET | DIN 02379473 |
| HYPERHEP B S/D | 220 UNIT | SOLUTION | GRIFOLS THERAPEUTICS LLC | CANCELLED POST MARKET | DIN 02230738 |
| HYPERHEP B S/D | 220 UNIT | SOLUTION | GRIFOLS THERAPEUTICS LLC | CANCELLED POST MARKET | DIN 02379465 |
| HYPERHEP INJ | LIQUID | CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | CANCELLED POST MARKET | DIN 00499617 |
Who else supplies HEPATITIS B IMMUNOGLOBULIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HEPATITIS B IMMUNOGLOBULIN appears in 66 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.